Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis

Published:2021-06-09 Issue: Volume: Page:
ISSN:2322-5939
Container-title:International Journal of Health Policy and Management
language:en
Short-container-title:Int J Health Policy Manag

Author:

Huang Cong¹^ORCID,Ung Carolina Oi Lam²,Wushouer Haishaerjiang¹³,Bai Lin¹,Li Xinyi¹,Guan Xiaodong¹^ORCID,Shi Luwen¹^ORCID

Affiliation:

1. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.

2. State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.

3. Center for Strategic Studies, Chinese Academy of Engineering, Beijing, China.

Publisher

Maad Rayan Publishing Company

Subject

Health Policy,Health Information Management,Leadership and Management,Management, Monitoring, Policy and Law,Health(social science)

Link

http://www.ijhpm.com/article_4060_064ea1dfc963362369bf078c9c82d440.pdf

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of national reimbursement anticancer medications availability in China: based on a medical institution perspective;BMC Public Health;2024-08-21

2. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data;BMC Public Health;2024-05-14

3. Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer;Frontiers in Immunology;2023-09-04

4. The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data;Journal of Global Health;2023-08-11

5. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study;Journal of Global Health;2022-12-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3